SELECT PUBLICATIONS

Boccardo F et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23(22):5138-47. Abstract

Cheung KL et al. Selection of primary breast cancer patients for adjuvant endocrine therapy — Is oestrogen receptor alone adequate? Breast Cancer Res Treat 2001;65(2):155-62. Abstract

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Robertson JFR et al. Effects of fulvestrant in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer Suppl 2004;2(3):73;Abstract 59.

Robertson JF et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61(18):6739-46. Abstract

Saphner T et al. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14(10):2738-46. Abstract

Thürlimann B et al; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353(26):2747-57. Abstract

Young O et al. Randomized pre-operative study of 750 mg of fulvestrant and 20 mg tamoxifen in premenopausal women with estrogen receptor-positive breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 5084.